Trulieve Marks NYSE First With Closing Bell Ceremony

Trulieve Cannabis Corp. will ring The Closing Bell at the New York Stock Exchange at 4:00 p.m. Eastern on August 18, 2026, marking its first day on the exchange floor as what the company describes as the first U.S. cannabis company listed on the NYSE. Founder and Chief Executive Officer Kim Rivers will be joined by members of the company’s board of directors and executive leadership for the ceremony, which celebrates a listing that took effect June 10, 2026, the company announced.

The bell ringing is ceremonial, but the milestone underneath it is not. For decades, federal law kept state-licensed cannabis companies off the major U.S. exchanges and pushed them onto the Canadian Securities Exchange and over-the-counter markets. Trulieve’s subordinate voting shares now trade under the ticker TRLV on the same exchange as the largest companies in the country.

“Ringing The Closing Bell at the New York Stock Exchange is an incredible honor and a proud moment for everyone who has contributed to Trulieve’s success,” Rivers said in the announcement. “Our NYSE listing represents the culmination of years of disciplined execution, operational excellence, and a commitment to creating long-term value for our shareholders.”

A video of the ceremony will be available on the NYSE’s website after the close, according to the company.

How Trulieve Got to the NYSE Floor

The path ran through a federal rescheduling order, a corporate breakup, and an exchange approval, in that order.

On April 23, 2026, the Justice Department issued an order immediately placing two categories of marijuana products in Schedule III of the Controlled Substances Act: FDA-approved drug products containing marijuana, and marijuana products regulated by a qualifying state medical marijuana license. Acting Attorney General Todd Blanche acted under the authority to reschedule drugs to carry out U.S. obligations under the Single Convention on Narcotic Drugs, following President Trump’s December 18, 2025 executive order on medical marijuana and cannabidiol research. Adult-use marijuana was not part of the order.

That distinction shaped what Trulieve did next. After the April order, the company completed a corporate restructuring and third-party investment that deconsolidated its operations in markets serving both medical and adult-use customers, leaving a consolidated business made up only of state-licensed medical marijuana facilities, according to its June 5, 2026 uplisting announcement. The DEA registered the company’s dispensaries under a medical marijuana dispensary registration process the agency stood up alongside the rule.

“Common sense action by President Trump to reclassify medical marijuana to Schedule III paved the way for this historic milestone,” Rivers said in the June announcement.

The NYSE approved the listing on June 5, 2026, and the shares began trading June 10, 2026, after the company’s listings on the Canadian Securities Exchange and the OTCQX market wound down at the close on June 9, 2026. The deconsolidation later produced a $403.3 million one-time accounting loss in Trulieve’s second-quarter report, its first as an NYSE-listed company; MyCannabis covered those results on August 7, 2026. The company also completed a redomiciliation to Delaware this month.

Trulieve by the Numbers

The figures below come from the company’s August 18 announcement and its second-quarter 2026 report:

• 207 medical dispensaries across Florida, Georgia, Pennsylvania, and West Virginia, all registered with the DEA
• 3.5 million square feet of cultivation and production capacity, supporting more than 5,000 employees
• $271 million in second-quarter revenue at a 60% gross margin, with adjusted EBITDA of $98 million
• $109 million in cash flow from operations in the first half of 2026, ending the quarter with $325 million in cash
• $50 million share repurchase program, capped at the lesser of that amount or 8,495,038 subordinate voting shares

Where Trulieve Is Expanding Next

The company points to two states as its next fronts. In Georgia, an expansion of the medical marijuana program under SB 220 accelerated patient enrollment and allowed Trulieve to launch new Modern Flower and Roll One branded vape and inhalable flower products through retail dispensaries and independent pharmacies. In Texas, the company says it has initial production capacity ready for final inspection and a retail pipeline spanning all 11 public health regions to serve patients under the Texas Compassionate Use Program once it receives final licensure.

Company-reported inspection milestones to date: DEA inspections are complete in Florida, Pennsylvania, and West Virginia.

What the Federal Order Left Undone

The April rescheduling is narrower than the word suggests, and the NYSE milestone sits inside its boundaries. The order covers FDA-approved products and state-licensed medical marijuana products only; adult-use marijuana remains in Schedule I. A separate DEA administrative hearing on the broader proposal to move all marijuana from Schedule I to Schedule III began June 29, 2026, with seven interested parties selected to participate, including Smart Approaches to Marijuana, the Tennessee Bureau of Investigation, and the states of Nebraska, Idaho, Indiana, and Louisiana.

For the rest of the industry, the exchange barrier has not moved. Other multistate operators are moving the same direction: Cresco Labs, which reported a $19 million tax benefit from the medical rescheduling on August 6, 2026, said it is preparing for a potential U.S. exchange uplisting now that Schedule III ‘opens a path to U.S. exchange listings.’ The NYSE ceremony Trulieve performs August 18 is, for now, a room of one.